Conference Coverage

Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients


 

REPORTING FROM ACOG 2018


“Any opportunity to prevent ovarian cancer is worthwhile,” Dr. Kwon commented. “If an ovarian cancer patient cannot be tested because she declines testing or, more commonly, because she is deceased, her first-degree relative should have BRCA mutation testing, regardless of other personal or family history or ethnicity.”

She and her coinvestigators reported no relevant financial disclosures.

Pages

Recommended Reading

VIDEO: Survival improves when cancer patients self-report symptoms
Breast Cancer ICYMI
Use of Pap smears, mammography on the decline
Breast Cancer ICYMI
Breast density and optimal screening for breast cancer
Breast Cancer ICYMI
Breast cancer screening: Is the controversy of benefits versus harms resolved?
Breast Cancer ICYMI
NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancers
Breast Cancer ICYMI
New multi-analyte blood test shows promise in screening for several common solid tumors
Breast Cancer ICYMI
Pembrolizumab plus SBRT shows promise for advanced solid tumors
Breast Cancer ICYMI
FDA authorizes first direct-to-consumer BRCA1/2 test
Breast Cancer ICYMI
How does oral contraceptive use affect one’s risk of ovarian, endometrial, breast, and colorectal cancers?
Breast Cancer ICYMI
VIDEO: Office-based hereditary cancer risk testing is doable
Breast Cancer ICYMI